Autonomix Medical (AMIX) Proxy filing summary

Executive summary

• Annual Meeting scheduled for October 30, 2025, with five key proposals for shareholder vote.

• Shareholders of record as of September 8, 2025, are eligible to vote in person or by proxy.

• Proxy materials are available electronically, supporting cost savings and environmental goals.

Voting matters and shareholder proposals

• Proposal 1: Election of five directors to serve until the 2026 annual meeting.

• Proposal 2: Ratification of Forvis Mazars, LLP as independent auditor for fiscal year ending March 31, 2026.

• Proposal 3: Amendment to authorize a reverse stock split at a ratio between 1-for-2 and 1-for-25, at Board discretion.

• Proposal 4: Approval of an amendment to the 2023 Equity Incentive Plan to increase authorized shares.

• Proposal 5: Approval to issue more than 20% of outstanding common stock under a purchase agreement with Lincoln Park Capital Fund, LLC, in compliance with Nasdaq rules.

Board of directors and corporate governance

• Board consists of five members, with a majority deemed independent under Nasdaq rules.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with independent members.

• Board and committees held a total of 22 meetings in fiscal 2025, with high attendance.

• Director nominations consider leadership, experience, and diversity of skills.